Who Paid My Doc
Leanne Alexander
Physician Assistant, Medical Springfield, VT Physician Assistant
NPI 1720429822 CMS profile 10987749
25 Ridgewood Rd, Springfield, VT 05156
General payments
$65
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Leanne Alexander of Springfield, VT is reported in the CMS Open Payments database as having received $65 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 19th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $65 | 1 |
Beside peers
- Leanne Alexander
- Physician Assistant, Medical median
- Middle half of Physician Assistant, Medical
- National median
In program year 2025, general payments to Leanne Alexander were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.
Show as a table
| Year | Leanne Alexander | Physician Assistant, Medical median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $61 | $19–$193 | $163 |
| 2020 | $0 | $20 | $14–$64 | $114 |
| 2021 | $65 | $156 | $41–$563 | $132 |
| 2022 | $0 | $185 | $55–$649 | $149 |
| 2023 | $0 | $199 | $58–$717 | $160 |
| 2024 | $0 | $206 | $62–$740 | $164 |
| 2025 | $0 | $214 | $62–$755 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
1,307
Drug cost
$125,319
Branded share of claims
36.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 98 | $66,146 | |
| Gemtesa Vibegron | Brand | 49 | $30,839 | |
| Tamsulosin Hcl | Generic | 377 | $7,481 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 142 | $3,248 | |
| Testosterone | Generic | 25 | $2,879 | |
| Finasteride | Generic | 173 | $2,736 | |
| Solifenacin Succinate | Generic | 52 | $2,313 | |
| Alfuzosin Hcl Er Alfuzosin Hcl | Brand | 104 | $2,272 | |
| Potassium Citrate Er Potassium Citrate | Brand | 17 | $2,258 | |
| Silodosin | Generic | 15 | $1,312 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Physician Assistant, Medical in Vermont
Practitioners in the same specialty and state, ranked by reported value.
All Physician Assistant, Medical
Everyone recorded under this specialty, nationwide.
Doctors in Vermont
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.